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Mourad Tighiouart and Andre´ Rogatko
Abstract. Traditionally, the major objective in phase I trials is to iden-
tify a working-dose for subsequent studies, whereas the major endpoint
in phase II and III trials is treatment efficacy. The dose sought is typ-
ically referred to as the maximum tolerated dose (MTD). Several sta-
tistical methodologies have been proposed to select the MTD in cancer
phase I trials. In this manuscript, we focus on a Bayesian adaptive
design, known as escalation with overdose control (EWOC). Several
aspects of this design are discussed, including large sample properties
of the sequence of doses selected in the trial, choice of prior distri-
butions, and use of covariates. The methodology is exemplified with
real-life examples of cancer phase I trials. In particular, we show in the
recently completed ABR-217620 (naptumomab estafenatox) trial that
omitting an important predictor of toxicity when dose assignments to
cancer patients are determined results in a high percent of patients
experiencing severe side effects and a significant proportion treated at
sub-optimal doses.
Key words and phrases: Cancer phase I trials, dose-limiting toxicity,
escalation with overdose control, tolerated dose, optimal Bayesian fea-
sible.
1. INTRODUCTION
The main objective in cancer phase I clinical tri-
als is to identify a tolerable dose of a cytotoxic or
therapeutic agent for subsequent studies. Phase I
trials represent the first testing of an investigational
agent or combination of agents whose safety profile
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has been established individually. These trials typ-
ically enroll patients with advanced cancer stages
and who have exhausted available standard treat-
ment options [24].
Cancer phase I trials are carried out sequentially,
assigning dose levels to subjects based on the ob-
served side effects of the previously treated patients.
From a safety and therapeutic perspective, these tri-
als should be designed to minimize the number of
unacceptable toxic events and maximize the num-
ber of patients treated at an optimal dose. Ideally,
the design should control the probability of over-
dosing patients at each stage of the trial, produce
a sequence of doses that converge to the MTD, and
should take into account the heterogeneous nature
of cancer phase I trial patients [29].
Decisions to escalate or de-escalate dose levels in
cancer phase I trials are made after one cycle of
therapy to patients. The length of a cycle is usually
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between 3 and 6 weeks. Therefore, the target phase
I dose is typically defined in terms of treatment-
related side effects, ignoring treatment efficacy. This
is due to the fact that treatment efficacy, expressed
as a reduction in tumor size or an increase in sur-
vival, requires months (if not years) of observation
[21, 34], a length of time far greater than the length
of one cycle of therapy. Thus, it can be stated that
the main objective of a cancer phase I clinical trial
is to determine a safe dose of a new drug or com-
bination of drugs for subsequent clinical evaluation
of efficacy. This dose is known as the maximum tol-
erated dose (MTD), or phase II dose. Specifically,
the MTD, γ, is defined as the dose expected to pro-
duce some degree of medically unacceptable, dose-
limiting toxicity (DLT) in a prespecified proportion
θ of patients [14],
P (DLT|Dose = γ) = θ.(1)
The target probability of DLT θ depends on the
severity of the treatment-attributable toxicity. It is
set relatively high when the DLT is reversible or
nonfatal condition, and low if it is life-threatening
[3]. Ting [33] and Rosenberger and Haines [27] gave
good reviews of statistical methods for dose find-
ing in cancer phase I trials. In particular, the widely
used continual reassessment method (CRM) proposed
by O’Quigley, Pepe and Fisher [21] and its exten-
sions by Faries [12], Goodman, Zahurak and Pi-
antadosi [15], Mo¨ller [19], Piantadosi, Fisher and
Grossman [23], and Storer [28], and the escalation
with overdose control (EWOC) method proposed by
Babb, Rogatko and Zacks [3], Zacks, Rogatko and
Babb [36], Babb and Rogatko [4], Tighiouart, Ro-
gatko and Babb [31] and Rogatko et al. [25] are
Bayesian adaptive and produce consistent sequences
of doses under some model assumptions and regu-
larity conditions. These designs can be easily imple-
mented in practice using published tutorials and free
interactive software; see, for example, the works of
Garrett [13], Zohar et al. [38], Xu, Tighiouart and
Rogatko [35], and Rogatko, Tighiouart and Xu [26].
In this article, we review several aspects of EWOC,
including large sample properties, choice of prior dis-
tributions, and use of covariates. The methodology
is exemplified with cancer phase I clinical trials we
designed and conducted at Fox Chase Cancer Center
in Philadelphia and the Winship Cancer Institute in
Atlanta.
This article is organized as follows. In Section 2,
we introduce the phase I design known as EWOC
and review its large sample properties. We illustrate
its implementation using a real-life example. An ex-
tension of this design to account for patients’ spe-
cific characteristics is described in Section 3 and the
methodology is illustrated by a recently completed
phase I cancer trial. Section 4 contains some con-
cluding remarks and discussion.
2. ESCALATION WITH OVERDOSE
CONTROL
Denote by Y the binary indicator of DLT for a
patient given dose x. Assume that there exist x∗
and x∗∗, x∗ <x∗∗ such that
P (Y = 1|x= x∗) = 0,(2)
P (Y = 1|x= x∗∗) = 1− ε,(3)
where 0< ε< 1 is known and θ < 1− ε.
Let F (z) be a strictly increasing cumulative dis-
tribution function (c.d.f.) having probability density
function f(z). We consider a dose-toxicity relation-
ship of the form
P (Y = 1|x)
(4)
= F
(
F−1(1− ε) + β log
(
x− x∗
x∗∗ − x∗
))
,
where β is unknown, and 0< β∗ ≤ β ≤ β∗∗ for some
positive real numbers β∗ and β∗∗. This model as-
sumes that the quantiles of F are linear in the log-
standardized dose z = log[(x − x∗)/(x∗∗ − x∗)]. An
example of F that is commonly used in practice is
the logistic model F (z) = ez/(1 + ez). It is easy to
verify that model (4) satisfies the constraints (2)
and (3). The condition β > 0 implies that the prob-
ability of DLT is an increasing function of dose. Let
φ= F−1(1− ε)−F−1(θ). Using (4), it can be shown
that the MTD γ defined in (1) is
γ = x∗ + (x∗∗ − x∗)e−φ/β .(5)
This also shows that γ ∈ [x∗, x∗∗]. Let γ′ = log((γ −
x∗)/(x∗∗−x∗)) be the MTD on the log-standardized
scale. Then (5) implies that γ′ =−φ/β.
2.1 Dose Escalation Based on Bayesian
Estimates
Let G(u) = F (F−1(θ) + φ + u), g(u) = G′(u) and
z1 =−φ/β
∗ be the level assigned to the first patient.
Then,
G(βz1) = F (F
−1(θ) + F−1(1− ε)−F−1(θ) + βz1)
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= F (F−1(1− ε) + βz1)
= P (Y = 1|z1)≤ F (F
−1(1− ε) + β∗z1)
= F (F−1(θ)) = θ,
since z1 < 0 and F (z) is strictly increasing. This
shows that this log-standardized dose z1 is safe in
the sense that the probability of DLT at this level
does not exceed θ. Let Dn = {(zi, Yi), i = 1, . . . , n}
be the data after enrolling n patients to the trial
where Yi is the observed DLT status of the patient
getting level zi, zi ∈L
∗ = [− φβ∗ ,−
φ
β∗∗ ].
Let h(β) be a prior density function for the pa-
rameter β on [β∗, β∗∗] and Πn(β) = Π(β|Dn) the
posterior c.d.f. given the data Dn. Let 0 < α < 1.
A sequence of dose levels zn such that
P (zn ≤−φ/β|Dn−1)≥ 1− α(6)
for all n≥ 2 is called Bayesian-feasible at level (1−
α); see the article by Zacks, Rogatko and Babb [36].
Let
z(α)n =−
φ
Π−1n−1(α)
, n≥ 2.(7)
Then, it is easy to verify that for all n ≥ 2, z
(α)
n
is Bayesian-feasible at level (1 − α). The choice of
z
(α)
n as the log-standardized dose levels in the trial
implies that the posterior probability of exceeding
the MTD is equal to the feasibility bound α. Let
Fn = σ(Dn) be the sigma-field generated by Dn and
ψ(α) be the class of all Bayesian-feasible sequences
zn ∈ Fn of level (1−α).
Definition 2.1. A sequence of levels {z∗n, n ≥
1} ∈ ψ(α) is called optimal Bayesian-feasible at level
(1− α), if for all N ≥ 1,
N∑
n=1
Eh{(γ
′ − z∗n)
+}= inf
{zn}∈ψ(α)
N∑
n=1
Eh{(γ
′ − zn)
+},
where z+ = zI(z > 0) denotes the positive part of a
random variable.
This means that z∗n minimizes the average amount
by which patients are underdosed. Using the law
of total expectation, Zacks, Rogatko and Babb [36]
showed that z
(α)
n is optimal Bayesian-feasible. Con-
ditions under which this sequence converges to the
true MTD in probability are stated in the next the-
orem.
Theorem 2.1. Suppose that for β0 ∈ [β
∗, β∗∗]:
1. 0< ε1 <G(−β0φ/β
∗)≤G(−β0φ/β
∗∗)≤ 1− ε.
2. 0 < ε2 < inf{g(β0x) :x ∈ L
∗} ≤ sup{g(β0x) :x ∈
L∗} ≤ g∗.
3. g(x) is continuously differentiable.
4. −∞ < inf{g′(β0x) :x ∈ L
∗} ≤ sup{g′(β0x) :x ∈
L∗}<∞.
5. h(β) is uniform on [β∗, β∗∗]. Then, z
(α)
n
p
−→−φ/
β0 as n→∞.
Proof. See the article by Zacks, Rogatko and
Babb [36]. 
2.2 Coherence of EWOC
Coherence of adaptive designs was introduced by
Cheung [7] in the context of cancer phase I clinical
trials. Due to ethical concerns, the dose of a cyto-
toxic agent for the next patient in a trial should
not be higher than the current allocated dose if the
current patient exhibits DLT. Likewise, the dose for
the next patient should not be lower than the cur-
rent one if the current patient does not exhibit DLT.
This desirable property is known as coherence and
Cheung [7] showed that CRM is coherent. The au-
thor also showed how the coherence property can
be lost when ad hoc modifications are introduced
to CRM. In this section, we show that EWOC as
described in Section 2.2 is coherent.
Let F (x,γ) = P (Y = 1|x) be the model given in
(4) reparameterized in terms of the MTD γ. Let
Dn = {(x1, Y1), . . . , (xn, Yn)} be the data generated
using the EWOC scheme described in Section 2.2.
This design is said to be coherent in escalation if for
all n≥ 2, xn ≥ xn−1 whenever Yn−1 = 0. The design
is said to be coherent in de-escalation if for all n≥
2, xn ≤ xn−1 whenever Yn−1 = 1. The design is said
to be coherent if it is coherent in both escalation
and de-escalation.
Theorem 2.2. Suppose that F (x,γ) is nonin-
creasing in gamma for fixed dose x. Then the EWOC
scheme described in Section 2.2 is coherent.
The proof of Theorem 2.2 is given in the Appendix.
It is easy to verify that the monotonicity condition
on F (x,γ) is satisfied by model (4), and in particu-
lar, the logistic function.
2.3 Two-Parameter Logistic Model
Denote by Xmin andXmax the minimum and max-
imum dose levels available for use in the trial. One
chooses these levels in the belief that Xmin is safe
when administered to humans. Babb, Rogatko and
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Zacks [3] considered a two-parameter logistic model
for the dose-toxicity relationship:
P (Y = 1|Dose = x) =
exp(β0 + β1x)
1 + exp(β0 + β1x)
,(8)
where we assume that β1 > 0 so that the probability
of DLT is a monotonic increasing function of dose.
Model (8) is reparameterized in terms of the MTD
γ and the probability of DLT at the starting dose
ρ0, parameters clinicians can easily interpret. This
might be advantageous since γ is the parameter of
interest and one often conducts preliminary studies
at or near the starting dose so that one can select a
meaningful informative prior for ρ0. Using the def-
inition of the MTD in (1) and (8), it can be shown
that
β0 =
Xmin logit(θ)− γ logit(ρ0)
xmin− γ
,
(9)
β1 =
logit(ρ0)− logit(θ)
xmin− γ
.
The second equation in (9) shows that the as-
sumption that β1 > 0 implies 0< ρ0 < θ.
2.3.1 Trial design After specifying a prior distri-
bution h(ρ0, γ) for (ρ0, γ), denote by Πn(γ) the
marginal posterior c.d.f. of γ given Dn. EWOC can
be described as follows. The first patient receives
the dose x1 = Xmin and conditional on the event
{y1 = 0}, the (n + 1)st patient receives the dose
xn+1 = Π
−1
n (α) so that the posterior probability of
exceeding the MTD is equal to the feasibility bound
α. If y1 = 1, we recommend that the clinician stops
the trial. Calculation of the marginal posterior dis-
tribution of γ is performed using numerical integra-
tion; see [3]. Often in practice, phase I clinical trials
are typically based on a small number of prespeci-
fied dose levels d1, . . . , dr. In this case, the (n+1)st
patient receives the dose
dˆn+1 = max
1≤i≤r
{di :di − xn+1 ≤ T1
and Πn(xn+1)− α≤ T2},
where T1, T2 are nonnegative numbers we refer to as
tolerances. We note that this design scheme does not
require that we know all patient responses before we
can treat a newly accrued patient. Instead, we can
select the dose for the new patient on the basis of
the data currently available. At the conclusion of
the trial, the MTD is estimated by minimizing the
posterior expected loss with respect to some suit-
able loss function l. One should consider asymmet-
ric loss functions since underestimation and overes-
timation have very different consequences. Indeed,
the dose xn selected by EWOC for the nth patient
corresponds to the estimate of γ having minimal risk
with respect to the asymmetric loss function
lα(x, y) =


α(γ − x),
if x≤ γ, that is, if x is an underdose,
(1− α)(x− γ),
if x > γ, that is, if x is an overdose.
Note that the loss function lα implies that for any
δ > 0, the loss incurred by treating a patient at δ
units above the MTD is (1 − α)/α times greater
than the loss associated with treating the patient at
δ units below the MTD. This interpretation might
provide a meaningful basis for the selection of the
feasibility bound. The above methodology can be
implemented using the user-friendly software of Ro-
gatko, Tighiouart and Xu [26].
2.3.2 Correlated priors on ρ0 and γ In models (4)
and (8), we assumed that the support of the MTD
was strictly contained in [x∗, x∗∗] and [Xmin,Xmax],
respectively. The assumption that γ is bounded from
above may be too restrictive. In the absence of toxi-
city, this assumption causes the dose escalation rate
to slow down and in general, the target MTD will
never be achieved if it lies outside the support of γ.
Furthermore, since the support of the probability of
DLT at the initial dose ρ0 is [0, θ] and γ is a function
of θ, the assumption of prior independence between
ρ0 and γ may not be realistic. Intuitively, the closer
ρ0 is to θ, the closer the MTD is toXmin. Tighiouart,
Rogatko and Babb [31] introduced a class of corre-
lated priors for h(ρ0, γ) on [0, θ]× [Xmin,∞) using
truncated normal distributions for the parameter γ.
They showed that a candidate joint prior for (ρ0, γ)
with negative a priori correlation structure results
in a safer trial than the one that assumes indepen-
dent priors for these two parameters while keeping
the efficiency of the estimate of the MTD essentially
unchanged.
2.4 EWOC with Varying Feasibility Bound
Many of the phase I cancer trials the authors de-
signed at Fox Chase Cancer Center and Winship
Cancer Institute used a variable feasibility bound
α; see the work of Babb and Rogatko [2, 4], Cheng
et al. [6], Tighiouart and Rogatko [29, 30], and Xu,
Tighiouart and Rogatko [35]. The rationale behind
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this approach is that uncertainty about the MTD
is high at the onset of the trial and a small value
of α offers protection against the possibility of ad-
ministering dose levels much greater than the MTD.
As the trial progresses, uncertainty about the MTD
declines and the likelihood of selecting a dose level
significantly above the MTD becomes significantly
smaller. However, design operating characteristics
were not studied. Chu, Lin and Shih [9] compared
the performance of different versions of CRM with
EWOC with both constant and varying α. The de-
sign of EWOC with varying α was termed “hybrid
design.” The authors conducted extensive simula-
tions to compare these designs in terms of (1) the
proportion of patients given doses above the “true”
MTD and (2) the proportion of times the recom-
mended dose is the “true” MTD after each patient
is enrolled in the trial and his or her DLT status is re-
solved. It was found in general that both the hybrid
and CRM designs had better convergence rate than
EWOC with fixed α and that EWOC with fixed and
varying feasibility bound α provide a better over-
dose protection than the CRM designs in the sense
that fewer patients are given doses above the “true”
MTD.
2.5 Example
EWOC was used to design a phase I clinical trial
that involved the R115777 drug at Fox Chase Can-
cer Center in Philadelphia, USA in 1999. R115777
is a selective nonpeptidomimetic inhibitor of farne-
syltransferase (FTase), one of several enzymes re-
sponsible for posttranslational modification that is
required for the function of p21(ras) and other pro-
teins. This was a repeated dose, single center trial
designed to determine the MTD of R115777 in pa-
tients with advanced incurable cancer. The target
probability of DLT was set to θ = 1/3. The dose-
escalation scheme was designed to determine the
MTD of R115777 when drug is administered orally
for 12 hours during 21 days followed by a 7-day
rest. This constitutes one cycle of therapy. Toxic-
ity was assessed by the National Cancer Institute
(NCI) Common Toxicity Criteria [20]. DLT was de-
termined by week 3 of cycle 1, as defined by Grade
III nonhematological toxicity (with the exception
of alopecia or nausea/vomiting) or hematological
Grade IV toxicity with a possible, probable or likely
causal relationship to administration of R115777.
Dosing continued until there was evidence of tumor
progression or DLT leading to permanent discontin-
uation. The initial dose judged to be safe by the clin-
ician for this study was Xmin = 60 mg/m
2 and the
maximum allowable dose was Xmax = 600 mg/m
2.
More details about the dosing regimen for this trial
can be found in the work of Tighiouart and Rogatko
[29]. Assuming vague priors for ρ0 on [0, θ] and γ on
[60,600], the prior probability density of (ρ0, γ) is
h(ρ0, γ)
=
{
1/180, if (ρ0, γ) ∈ [0,1/3]× [60,600],
0, otherwise.
Thus, ρ0 and γ are independent a priori, uniformly
distributed over their corresponding interval. Figure
1 shows the posterior distributions of the MTD as
the trial progressed and Figure 2 shows the pos-
terior density of the MTD after 33 patients have
been treated. The posterior mode is 323 which cor-
responds to the 47th percentile of the distribution.
In this trial, we used a variable feasibility bound α,
starting with α= 0.3, this value being a compromise
between the therapeutic aspect of the agent and its
toxic side effects. As the trial progressed, α increased
in small increments until α= 0.5 so that, by the end
of the trial, the given dose corresponds to the 50th
percentile, that is, the median of the marginal poste-
rior probability density function. Thus, the dose to
be given to the 34th patient is 328. The 95% highest
posterior density interval is [160.5,536.1].
3. ADJUSTING FOR PATIENTS’ BASELINE
COVARIATES
A key assumption implied by the definition of the
phase I target dose (MTD) is that every subgroup of
the patient population has the same MTD. That is,
it is assumed that the patient population is homo-
geneous in terms of treatment tolerance and every
patient should be treated at the same dose. As a
result, no allowance is made for individual patient
differences in susceptibility to treatment [11].
Babb and Rogatko [4] extended EWOC to allow
the incorporation of information concerning individ-
ual patient differences in susceptibility to treatment.
The method adjusts doses according to patient-specific
characteristics while safeguarding against overdos-
ing.
3.1 Model
Let W be a p-dimensional baseline covariate vec-
tor. We consider the dose-toxicity model
P (Y = 1|Dose = x,W =w)
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Fig. 1. Posterior density of the MTD when the
number of treated patients (from bottom to top) is
1,5,10,15,20,25,30,33.
Fig. 2. Posterior density of the MTD after 33 patients have
been treated. The posterior mode is 323 (47th percentile) and
the median and dose to be given to the 34th patient is 328.
The 95% highest posterior density interval is [160.5,536.1].
(10)
=
exp(β0 + β1x+ η
′w)
1 + exp(β0 + β1x+ η′w)
,
where η ∈ Rp is the effect of the baseline covari-
ate vector on DLT. Let px(w) = P (Y = 1|Dose =
x,W = w). We assume that β1 > 0 so that px(w)
is an increasing function of dose x for fixed w. The
MTD for a patient with baseline covariate value w
is defined as the dose γ(w) that results in a proba-
bility equal to θ that a DLT will manifest. It follows
from model (10) that
γ(w) = β−11
[
log
(
θ
1− θ
)
− β0 − η
′w
]
.(11)
As in Section 2.3, we reparameterize this model
in terms of (γ(w∗), ρ) for a selected value of the
baseline covariate vector w=w∗ and ρ is a (p+1)-
dimensional nuisance parameter.
3.1.1 Trial design Let h(ρ, γ(w∗)) be a prior dis-
tribution for (ρ, γ(w∗)) and denote by Πn,w∗(γ(w
∗))
the marginal posterior c.d.f. of γ(w∗) given the data
Dn = {(x1, Y1,w1), . . . , (xn, Yn,wn)}. The first patient
receives the dose x1 =Xmin and conditional on the
event {y1 = 0}, the (n+1)st patient with covariate
vector value wn+1 receives the dose xn+1 =
Π−1n,wn+1(α) so that the posterior probability of ex-
ceeding the MTD is equal to the feasibility bound
α. Note that here, Π−1n,wn+1(·) is the inverse c.d.f. of
Πn,wn+1(γ(wn+1)).
For a binary covariate W , Tighiouart, Rogatko
and Xu [32] studied operating characteristics of this
model with extensive simulations under different sce-
narios for the underlying true MTDs. They found
that if the two MTDs are different and the design
does not adjust for this heterogeneity, then the trial
will result in more patients being overdosed. If the
two MTDs are different and parallel trials are used,
then the estimates of the MTDs are less efficient. Fi-
nally, if the two MTDs are the same and the design
adjusts for patients’ heterogeneity, then few more
patients can be overdosed if the true MTD is low
relative to a design with no covariate but the differ-
ence is not practically important. Thus, we stand to
lose little if we do include a statistically nonsignif-
icant covariate in the model. This conclusion is in
agreement with the findings of O’Quigley, Shen and
Gamst [22].
3.2 Example
ABR-217620 (naptumomab estafenatox) is a re-
combinant fusion protein that consists of the 5T4Fab
moiety genetically fused to the engineered super-
antigen variant SEA/E-120. This fusion protein is a
new generation tumor-targeted superantigen based
on the previously described ABR-214936
(anatumomab mafenatox). ABR-217620 was
designed to reduce antigenicity and toxicity. We use
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Fig. 3. Dose allocation as a function of baseline Anti
SEA/E120 during the trial for all 39 patients. The solid line is
the MTD conditional on the covariate Anti SEA/E120 which
corresponds to the posterior median of the conditional poste-
rior distribution of the MTD and the dashed lines delimit the
95% Bayesian credible region.
model (10) with W = C representing the Anti
SEA/E120 covariate to design a phase I study for
nonsmall cell lung cancer (NSCLC) patients. The
goal is to determine the MTD of ABR-217620 as a
function of patients’ baseline Anti SEA/E120 and
test whether the neutralizing effect of Anti SEA/
E120 on the cytotoxic agent which was observed by
Babb and Rogatko [4] has been reduced or elimi-
nated with this new agent. The modeling approach
is similar to the PNU trial described in [4], the tar-
get probability of DLT θ was set to 0.2. The fea-
sibility bound α was set at 0.25 for the first nine
patients, then was increased to a maximum value
of 0.5 by increments of 0.05 every time a new pa-
tient was enrolled in the trial and a DLT assessment
was resolved. Based on preliminary clinical data, the
minimum and maximum allowable doses for ABR-
217620 set by the clinicians are xmin = 1 ug/kg and
xmax = 100 ug/kgl. The minimum and maximum
values of Anti SEA/E120 anticipated in the trial are
c1 = 0 pmol/ml and c2 = 200 pmol/ml, respectively.
As in the PNU trial [4], we reparameterize model
(10) in terms of γmax = γ(c2), ρ1 = pxmin(c1), ρ2 =
pxmin(c2) with (γmax, ρ1, ρ2) uniformly distributed on
{(x, y, z) :y ∈ (0, θ], z ∈ (0, y), x ∈ [1,100]} a priori.
Figure 3 shows the doses allocated to all 39 pa-
tients as a function of their pretreatment Anti
Fig. 4. Dose allocation as a function of baseline Anti
SEA/E120 during the trial for all 28 NSCLC & PC patients.
The solid line is the MTD conditional on the covariate Anti
SEA/E120 which corresponds to the posterior median of the
conditional posterior distribution of the MTD and the dashed
lines delimit the 95% Bayesian credible region.
SEA/E120. The solid line is the estimated condi-
tional MTD, obtained by taking the posterior me-
dian of the marginal distribution of the MTD condi-
tional on the covariate Anti SEA/E120. The dashed
lines delimit the 95% Bayesian credible region. Six
patients experience DLT (15.4%) and the MTD seems
to indicate that the neutralizing effect of Anti
SEA/E120 has been reduced considerably. The pro-
tocol was amended to include patients with renal cell
(RCC) and pancreatic cancer (PC). Figures 4 and 5
show the doses allocated to NSCLC & PC patients
and RCC patients, respectively. The solid line repre-
sents the conditional MTD obtained after fitting the
data in each group to model (10), reparameterized
in terms of (γmax, ρ1, ρ2). This shows that NSCLC
& PC patients were treated at sub-optimal doses
and RCC patients were overdosed, with 36.4% ex-
periencing DLT, way above the target probability of
DLT θ = 0.2.
The effects of Anti SEA/E120 and type of cancer
were tested by fitting model (10) with W = (C,Z),
where C is the baseline Anti SEA/E120 and Z is a
binary covariate representing the cancer type, Z =
z1 = 1 for NSCLC and PC patients and Z = z2 = 0
for RCC patients. To be consistent with the pri-
ors used to design the trial, we reparameterized the
model in terms of γmax = γ(c2, z1), ρ1 = pxmin(c1, z1),
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Fig. 5. Dose allocation as a function of baseline Anti
SEA/E120 during the trial for all 11 RCC patients. The solid
line is the MTD conditional on the covariate Anti SEA/E120
which corresponds to the posterior median of the conditional
posterior distribution of the MTD and the dashed lines delimit
the 95% Bayesian credible region.
ρ2 = pxmin(c2, z1) and ρ3 = pxmin(c1, z2). Independent
uniform priors are placed on these parameters. It
can be shown that this induces priors centered at 0
for the Anti SEA/E120 and cancer type effect pa-
rameters η1 and η2. We used WinBUGS [18] to fit
this model and the 95% HPD intervals for the pa-
rameters η1 and η2 were (−0.14,0.24) and (−4.6,0.6),
respectively. We conclude that the agent ABR-217620
was successful in reducing the neutralizing capacity
of Anti SEA/E120 and that the phase II dose should
be carefully tailored to account for patients’ cancer
type and hence avoid excessive overdosing and un-
derdosing patients.
4. DISCUSSION
In this article, we described EWOC, a Bayesian
dose finding design for cancer phase I clinical trials.
The method is flexible enough to allow prior infor-
mation about the drug from laboratory or animal
studies to be incorporated in the model, is coher-
ent, makes use of all the information available at the
time of each dose assignment and controls the prob-
ability of overdosing patients at each stage. EWOC
can be implemented with the user-friendly software
EWOC 2.1 [26] or WinBUGS [18] for general class
of prior distributions [31]. The two-parameter model
described in Section 2.3 accounts for the uncertainty
regarding the probability of DLT at the initial dose
by placing a vague prior distribution on ρ0. If ex-
pert opinion about this parameter is available, then
it should be incorporated in the prior for ρ0. In par-
ticular, if the clinician strongly believes that this
prior can be approximated by a point mass distri-
bution, then the one-parameter model described in
Section 2.1 may be used. In any case, design op-
erating characteristics should be performed with a
sensitivity analysis about the parameter ρ0 when
designing the trial. Our own experience in design-
ing dose-finding studies in cancer is that the uncer-
tainty of the clinicians regarding the probability of
DLT at the initial dose is large. Thus, in more than
ten years of designing trials with EWOC, the use
of a one-parameter model was never chosen by the
clinical researchers we worked with.
It is worth highlighting that the values of α and
θ are chosen independently when the trial is de-
signed. They have distinct meanings and functions.
For example, taking a value of α greater than θ
only affects the loss function used to estimate the
next dose and the MTD at the conclusion of the
trial. It does not mean that patients are given doses
at a rate above the target probability of DLT θ.
When α= 0.5, the method differs from CRM in the
sense that the loss functions are different. The loss
function for EWOC is taken with respect to the pa-
rameter γ, the MTD. The overprotection property
of EWOC is with respect to the posterior distribu-
tion of the MTD, given the data. The overprotection
property states that the posterior probability of ex-
ceeding the MTD given the current data is bounded
by α. This overprotection is as good as the posterior
distribution of the MTD at each stage of the trial.
For instance, if we used a flat prior on the MTD
and the true MTD turns out to be very close to the
initial dose, then it would take many patients for
the median of the posterior distribution to cluster
around the true MTD.
Another aspect of cancer phase I clinical trials not
discussed here is the choice of the number of patients
to enroll. Most sample size recommendations in the
literature are based on prespecified stopping rules;
see, for example, the work of Zohar and Chevret
[37] on selecting the number of patients by consid-
ering different stopping rules using the CRM. Lin
and Shih [17] and Ivanova [16] described sample size
recommendations based on the expected number of
patients allocated to each dose selected from a set
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of prespecified dose levels. However, these methods
apply to a prespecified set of discrete doses and it
is not clear how they can be applied to continu-
ous doses. Unlike the frequentist approach, there is
no consensus on a specific Bayesian method for the
sample size determination problem; see the article
by Adcock [1] for a review of Bayesian approaches.
We conducted extensive simulation studies in order
to estimate the sample size based on a desired ac-
curacy of the Bayes estimate on the average. Specif-
ically, we determined the minimum number of pa-
tients so that the posterior variance of the MTD on
the average over all possible trials is no more than
a specified margin. Tabulated values of the average
mean posterior standard deviation, length of 90%
and 95% HPD intervals for different values of the
target probability of DLT θ are available from the
authors upon request.
The methodology described in this article assumes
that DLT status is binary and does not account for
patients’ time to toxicity. Information on time to
DLT is crucial to clinicians in that it permits a dy-
namic updating of the posterior distribution of the
MTD based on the number of patients who experi-
enced DLT and the ones who are still at risk. If new
patients are eligible to enter the clinical trial while
the DLT status of currently enrolled patients is still
being resolved, then the new patients are allocated
to the current established dose because it is not eth-
ical to resolve DLT status at the expense of treat-
ment delay. In this case, there is no adaptation to
the most current information and the design will not
be efficient. Time to DLT was first investigated by
Cheung and Chapell [8] and later adapted to estima-
tion of a maximum cumulative dose by Braun et al.
[5]. These methods are extensions of the CRM and
incorporate information on partially observed pa-
tients using weighted binomial likelihoods. EWOC
can be adapted to this framework by modeling time
to DLT as a Cox [10] type model with a paramet-
ric or nonparametric baseline risk of toxicity h0(t).
We are currently investigating the performance of
a large class of models within this framework via
extensive simulations.
APPENDIX
Proof of Theorem 2.2. Let Πn(t) be the pos-
terior c.d.f. of γ given Dn, n≥ 2. Then, it suffices to
show that:
1. Πn(t)≤Πn−1(t) for all t whenever Yn = 0.
2. Πn(t)≥Πn−1(t) for all t whenever Yn = 1.
Let
Ln(γ|Dn) =
n∏
i=1
(F (xi, γ))
Yi(1−F (xi, γ))
1−Yi
be the likelihood function and h(γ) be a proper
prior distribution for γ. To simplify notation, let
Ln(γ|Dn) = Ln(γ), Fi(γ) = F (xi, γ) and suppose that
x∗ = 0, x∗∗ = 1. Using Bayes’ rule, the posterior c.d.f.
Πn(t) given Dn is
Πn(t) =
∫ t
0 Ln(γ)h(γ)dγ∫ 1
0 Ln(γ)h(γ)dγ
.
Suppose that Yn = 0. Then, Ln(γ) = Ln−1(γ)(1−
Fn(γ)) and
Πn(t) =
∫ t
0 Ln−1(γ)(1−Fn(γ))h(γ)dγ∫ 1
0 Ln−1(γ)(1−Fn(γ))h(γ)dγ
.
It follows that
Πn(t)−Πn−1(t)
=
∫ t
0 Ln−1(γ)(1− Fn(γ))h(γ)dγ∫ 1
0 Ln−1(γ)(1− Fn(γ))h(γ)dγ
−
∫ t
0 Ln−1(γ)h(γ)dγ∫ 1
0 Ln−1(γ)h(γ)dγ
=A−1
[∫ t
0
∫ 1
0
Ln−1(γ)Ln−1(γ
′)h(γ)h(γ′)
× [Fn(γ
′)− Fn(γ)]dγ
′ dγ
]
,
where
A=
∫ 1
0
∫ 1
0
Ln−1(γ)(1− Fn(γ))h(γ)
Ln−1(γ
′)h(γ′)dγ′ dγ,
Πn(t)−Πn−1(t)
=A−1
∫ t
0
∫ t
0
Ln−1(γ)Ln−1(γ
′)h(γ)h(γ′)
× [Fn(γ
′)−Fn(γ)]dγ
′ dγ
+A−1
∫ t
0
∫ 1
t
Ln−1(γ)Ln−1(γ
′)h(γ)h(γ′)
× [Fn(γ
′)−Fn(γ)]dγ
′ dγ
=A−1
∫ t
0
∫ 1
t
Ln−1(γ)Ln−1(γ
′)h(γ)h(γ′)
× [Fn(γ
′)−Fn(γ)]dγ
′ dγ ≤ 0,
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since Fn(γ) is nonincreasing in γ. Hence, Πn(t) ≤
Πn−1(t), which implies that Π
−1
n (α)≥Π
−1
n−1(α), that
is, xn+1 ≥ xn. Using a similar argument, one can
show that Π−1n (α)≤Π
−1
n−1(α) if Yn = 1. This shows
that EWOC is coherent. 
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